Page 2 - Angelini Beauty News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Angelini Pharma acquires Arvelle Therapeutics to create a leading European innovator in Central Nervous System (CNS) and Mental Health Disorder treatments
- Angelini Pharma and Arvelle Therapeutics have today agreed on a definitive merger agreement valuing Arvelle Therapeutics at up to $960 million
- Angelini Pharma will become a leading player amongst companies focused on Central Nervous System (CNS) and mental health disorder treatments
- Opening direct affiliates in France, UK, Nordics and Switzerland by 2022
News provided by
Share this article
ROME, Jan. 14, 2021 /PRNewswire/  
Angelini Pharma, an international pharmaceutical company which is a part of the private Italian Angelini Group – and ....

United States , South Korea , United Kingdom , Mark Altmeyer , Thea Paola Angelini , Angelini Pharma , Pierluigi Antonelli , Sergio Marullo , Angelini Pharma Inc , Sidley Austin , Sk Group , Angelini Holding , Sk Biopharmaceuticals Co Ltd , Mental Health , Drug Administration , Hero Group , Angelini Group , Korea Stock Exchange , Ysk Holdings , Centerview Partners United Kingdom , Procter Gamble , White Case Europe , Promising Innovative Medicine , Central Nervous System , Arvelle Therapeutics , For Angelini Pharma ,